What's New | Decker

The Hemodialysis Reliable Outflow (HeRO) graft (Hemosphere/CryoLife Inc, Eden Prairie, MN) is an innovative approach to obtain permanent AV access in patients with subclavian and internal jugular venous occlusions not amenable to open or endovascular means of recanalization.
In 2016, data from the United States Renal Data System (USRDS) showed that 124,675 new patients began therapy for ESRD, whereas the prevalent dialysis population reached 726,331. Of note, after a continuous rise in ESRD patients between 1980 and 2010, for the first time a plateau or even slight decline was seen between 2010 and 2016.
A common tradeoff for the higher long-term patency rates associated with autogenous AV access is failure of maturation of the outflow vein, leading to inadequate venous dilation and either inability to successfully use the AV access for dialysis or early AV access failure. Initial success rates leading to a functional AV access range from 55 to 97%.

Huma Farid, MD

The advent of the HPV vaccination has the potential to impact the incidence of cervical cancer. The vaccine was found to have 100% efficacy against CIN 3+ associated with HPV 16 or 18, and 93% efficacy against CIN 3+ due to other HPV types. The vaccination represents an important step forward in the prevention of HPV infection and cervical cancer.
The ability to genotype HPV and test for high risk HPV types has changed the management of abnormal cervical cytology. HPV cotesting has enhanced the sensitivity of pap smears and has enabled providers to triage which patients should be managed with colposcopy.
The success of HPV genotyping has led to the proposal of primary HPV testing instead of primary pap smear screening, as primary HPV testing has been found to be more sensitive than cytology.

Kimberly A Davis, MD, MBA, FACS, FCCM

CT Scan work-up of cholecystitis is not considered first line imaging for cholecystitis, although the use is prevalent because multiple sources of abdominal pain can be evaluated at the same time.
Percutaneous cholecystostomy may be definitive treatment for acalculous cholecystitis.
Antibiotics should be initiated within 1 hour for patients with hemodynamic instability or organ failure due to acute cholangitis or cholecystitis.
Early laparoscopic cholecystectomy is advocated for all but very frail or hemodynamically unstable patients with calculous cholecystitis.

The Endocrine Society Clinical Practice Guidelines recommend umbilical cord blood sampling only when fetal thyroid disease cannot be diagnosed based on clinical or sonographic data.
In 2009, the US FDA issued a warning on PTU-associated hepatotoxicity, prompting the American Thyroid Associated and the American Association of Clinical Endocrinologist to recommend initiation of PTU in the first trimester, followed by transition to methimazole in the second trimester.
Neonatal hyperthyroidism develops in approximately 1% of babies born to women with Graves disease.

Kimberly A Davis, MD, MBA, FACS, FCCM

CT Scan work-up of cholecystitis is not considered first line imaging for cholecystitis, although the use is prevalent because multiple sources of abdominal pain can be evaluated at the same time.
Percutaneous cholecystostomy may be definitive treatment for acalculous cholecystitis.
Antibiotics should be initiated within 1 hour for patients with hemodynamic instability or organ failure due to acute cholangitis or cholecystitis.
Early laparoscopic cholecystectomy is advocated for all but very frail or hemodynamically unstable patients with calculous cholecystitis.

Injections: trigger point and steroid injections help with neck pain. The analgesic and antiinflammatory effects help with patient recovery.
Radiofrequency ablation is a modality that has emerged for long term treatment of axial neck pain. This denervates the joint, resulting in less pain transmission.
Disk procedures function to remove the bulge or extruding portion of a disk from compressing nerves or the spinal cord.

Elucidation of HLA classes and their role in the complex (with mHAgs, etc) mechanisms of graft rejection have posited different approaches for immunosuppression to maintain graft survival in a recipient.
Multiple agent approach for complex immunomodulation of recipient immune system, including agents cyclosporine, tacrolimus, belatacept, basiliximab, sirolimus, everolimus, MPA, and alemtuxumab.
Detailed 2017 Renal Association guidelines delineate strategies, first-line and second-line choices for induction and maintenance immunosuppressive therapies in kidney transplant recipients. Furthermore, this guideline details the approach to management of rejection [see Table 13].

Dialytic Therapies